Skip to main content

Day: March 15, 2022

Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral DYRK1A inhibitor, a portfolio of novel STING inhibitors, and a next-generation kinase inhibitor platform On track to initiate Phase 1 study for BBI-02 for the treatment of autoimmune and inflammatory diseases in Q2 2022, with SAD and MAD topline results anticipated year-end 2022 New Drug Application (NDA) submission to the U.S. FDA for sofpironium bromide gel, 15% expected in mid-2022 BOULDER, Colo., March 15, 2022 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...

Continue reading

Acerus Reports Fourth Quarter and Full Year 2021 Financial Results

TORONTO, March 15, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and twelve-month period ended December 31, 2021. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Recent HighlightsTotal Natesto® prescriptions in the US rose 20% year-over-year in the fourth quarter of 2021 and, for the full year, were up approximately 28% over fiscal 2020 The rollout and acceptance of Natesto® continues to grow in the US, now benefitting from nearly complete in-person sales interaction as the pandemic subsides After the quarter, the Company announced it had increased its secured loan facility (the “Loan Facility”) from US$25 million to...

Continue reading

XCPCNL Business Services Announces LOI to Acquire Centiment Capital Holdings

Charlotte, North Carolina, March 15, 2022 (GLOBE NEWSWIRE) — XCPCNL Business Services Corporation (OTC Pink: XCPL), a venture development business that leverages knowledge, skill, and experience in the consumer products industry, is excited to announce a letter of intent to acquire Centiment Capital Holdings. Centiment Capital is the world’s first neurotech-enabled, for-profit, anti-bias-driven machine learning company. Centiment is built on understanding neuro-data-driven problems in artificial intelligence and utilizing neuroscience-driven tools, technology and apparatus to solve them. “We are excited about the opportunity to build shareholder value and enhance the current portfolio of Centiment Capital. We look forward to building additional revenue models with the assets we seek take over. Centiment is currently valued...

Continue reading

Xtant Medical to Present at the Canaccord Musculoskeletal Conference on March 22, 2022

BELGRADE, Mont., March 15, 2022 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, President and Chief Executive Officer, will present at the Canaccord Musculoskeletal Conference on Tuesday, March 22, 2022, at 2:00 p.m. Central Time in Chicago. A live webcast of the presentation will be available on the Investors section of the Company’s website or through the conference site by using the link below: Date: Tuesday, March 22, 2022Time: 2:00 p.m. CT / 3:00 p.m. ETWebcast: Click Here A replay of the webcast will be available for approximately 90 days on the Company’s website at www.xtantmedical.com following the conclusion of the presentation. About Xtant Medical Holdings, Inc. Xtant...

Continue reading

GBT Filed a Non-Provisional Patent – AI Empowered, Long-Range, Radio system

The patent seeks to provide comprehensive IP protection for intelligent, long range radio technology, including architecture, concepts, and methods SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT” or the “Company”), filed a non-provisional patent, application #17686461, for its long range, intelligent radio system, which has been assigned an internal code name Infinia. The patent seeks to protect a long-range data and voice communication system, that is operating via High Frequency (HF) radio waves. The technology intends to communicate through an ionospheric propagation environment to reach very long distances. The design incorporates AI systems and methods to overcome long range HF radio major challenges including skip zones, where there is no reception. The proposed dead-zone solution...

Continue reading

Caladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., March 15, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three months and twelve months ended December 31, 2021, on Tuesday, March 22, 2022, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below. Dial-in information: Conference ID: 5066195U.S. Toll-Free: 866-595-8403International: 706-758-9979 Please dial-in 10 minutes before the start of the conference call. A live webcast of the call will also be accessible under the Investors & News section of the Caladrius website (https://ir.caladrius.com)...

Continue reading

Lightbridge CEO Seth Grae to Participate in Panel Discussion at SXSW 2022

Panel to Discuss “Fueling the Future Food System; People, Power & Purpose” RESTON, Va., March 15, 2022 (GLOBE NEWSWIRE) — Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, announced that President and CEO Seth Grae will participate in a panel at SXSW called “Fueling the Future Food System; People, Power & Purpose” on Friday, March 18 at 11:40 am CT (12:40 pm ET). The panel will be moderated by Dr. Sweta Chakraborty, President of We Don’t Have Time U.S., and an Independent Director and Chair of the ESG Committee of the Board of Lightbridge. Mr. Grae will also participate in investor meetings throughout the event. The panel is part of Future of Food, an official SXSW event spanning two full days of programming on March 17 and 18 at the SXSW Center. The event will bring together a diverse...

Continue reading

Asia Broadband Prepares For Imminent Launch of Mobile App Versions of Proprietary Cryptocurrency Exchange

LAS VEGAS, March 15, 2022 (GLOBE NEWSWIRE) — Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce that the Company is anticipating the launch of its AABB Exchange mobile applications on the Apple and Android stores before March 22, 2022. The Company’s digital assets developer is currently finalizing the mobile versions of the proprietary cryptocurrency Exchange to submit for approval. The Exchange will soon be available to users on their mobile phones to place buy and sell orders to execute cryptocurrency trades for an expanding number of trading pairs available on the Exchange platform. Currently, users can access the Desktop version of the AABB Exchange by going to: https://aabbexchange.com/trade/ then on the right side of the monitor, click on “Log In or Register Now to trade”. Once you...

Continue reading

Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial

Treatment with AL001 (latozinemab) demonstrated target engagement and resulted in increases in progranulin levels in all patients FTD-C9orf72 patients treated with latozinemab demonstrated a trend toward a delay in disease progression relative to the ALLFTD matched control cohort First clinical dataset in an indication where latozinemab elevated progranulin above physiological levels Company to host webcast to review results today at 8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented results from the INFRONT-2 Phase 2 clinical trial of AL001 (latozinemab) in frontotemporal dementia patients (FTD) with a C9orf72 genetic mutation (FTD-C9orf72) at the AD/PD™ 2022 International Conference on Alzheimer’s...

Continue reading

Springs Rejuvenation Inc. Establishes Partnership with American Top Team Company

SPRJ Trainer George Mathews, Owner/head coach Roan “Jucao” Carneiro and Dr Charles PereyraAtlanta, GA, March 15, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Springs Rejuvenation Inc. (OTC: SPRJ), announced a partnership with American Top Team, a leading gym for MMA, BJJ and Fitness Training, by providing stem cell therapies and treatments to their members and competitive athletes.  Dr Charles Pereyra, Springs Rejuvenation Founder and Chief Operating Officer, stated, “I am excited for the opportunity to partner with American Top Team which is one of the world’s premier facilities for training elite combat athletes, including both UFC and Bellator Champions. I’ve personally been involved in mix martial arts and competition for many years, and I am familiar with the injuries, treatments and therapies needed to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.